The global Bruxism Management Market is anticipated to grow at a fast pace by reaching USD 5.3 Billion in 2022. As per Future Market Insights (FMI), the market is likely to be valued at USD 10.1 Billion in 2032 and exhibit growth at a CAGR of 6.9% in the forecast period from 2022 to 2032.
The rising prevalence of obstructive sleep apnea is set to augment the demand for bruxism management techniques in the near future.
| Report Attribute | Details |
|---|---|
| Bruxism Management Market Estimated Base Year Value (2021) | USD 4.8 Billion |
| Bruxism Management Market Expected Market Value (2022) | USD 5.3 Billion |
| Bruxism Management Market Anticipated Forecast Value (2032) | USD 10.1 Billion |
| Bruxism Management Market Projected Growth Rate (2022 to 2032) | 6.9% CAGR |
Bruxism is when a person clenches, grinds, or gnashes their teeth while not chewing. It often occurs during sleep, but it can also happen during waking hours. The person is usually not consciously aware that they are doing it.
Various symptoms of bruxism include broken or loose fillings, a dull headache, facial pain, worn teeth, jaw pain, and similar others. It is a common condition in young children when their teeth are growing.
Another main cause of bruxism in adults is stress. The usage of caffeine and alcohol can also lead to bruxism. In some individuals, it happens if they have a missing tooth or if their bite is not aligned.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The rising prevalence of neurological disorders, such as Parkinson’s and Huntington’s disease among the geriatric population is a vital factor that is likely to push sales of bruxism management devices in the evaluation period.
As per Parkinson’s Foundation, more than 10 million people are currently living with the disease across the globe. This number is estimated to grow at a steady pace, thereby propelling the market.
In addition to that, the growing cases of sleep apnea are expected to contribute to the global market growth. The American Sleep Apnea Association mentions that about 22 million people suffer from sleep apnea every year in the USA. alone.
Out of this, nearly 80% cases of severe and moderate obstructive sleep apnea remain undiagnosed. Spurred by the aforementioned factors, the global market is set to grow at a fast pace.
Researchers have found that medications are not very effective for the treatment of bruxism. Thus, they are striving to manage the consequences of this condition by promoting preventative measures. It involves the utilization of occlusal splints, mandibular advancement devices, stress management, and similar other devices.
A wide range of medications and muscle relaxants are being used to treat sleep bruxism. However, these medications can cause numerous side-effects, such as muscle weakness, nausea, and constipation. Also, bruxism mouth guards often ground down with time.
The unavailability of effective treatment options may hence hamper the global bruxism management market growth.
Principal Consultant
North America is set to dominate in the near future by accounting for the largest bruxism management market share. Rising stress and anxiety among the populaces in the USA. and Canada is one of the major factors that is expected to bode well for the regional market.
As per the National Alliance on Mental Illness, more than 40 million adults have an anxiety disorder in the USA. Likewise, nearly 7% of children belonging to the age group of 3 to 17 years, experience various issues with anxiety every year in the country. This trend is projected to continue throughout the forthcoming years, thereby boosting the regional market.
At present, Asia Pacific has a relatively low penetration for bruxism treatment products. Governments of various countries, such as India, China, South Korea, and Japan are investing huge sums to develop their healthcare infrastructure.
Many international companies are expected to set up their manufacturing facilities in these countries owing to the easy availability of low-cost labor and raw materials.
The increasing prevalence of sleeping bruxism across Asia Pacific is another major factor that is set to fuel the growth. The rising workplace stress and rapidly changing lifestyle in this region are also projected to expand the Asia Pacific bruxism management market size.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Some of the renowned companies present in the global bruxism management market are F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Eli Lilly and Company, Mayne Pharma, Cadila Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Pfizer, Endo International plc, Akervall Technologies, Inc., and Mylan N.V. among others.
Majority of the companies operating in the global market are increasingly focusing on research and development activities to introduce cutting-edge bruxism treatment options. The market is projected to witness the entry of several start-up companies that would target the infant population and come up with new medications for them.
In June 2021, for instance, SelfSense Technologies, an Irish start-up firm, announced its plan to close a €1 million funding round by launching its new intelligent mouth guards in Europe and Ireland.
The company aims to cater to the needs of patients suffering from bruxism by providing them with innovative guards. Thus, the increasing number of new product launches by start-up companies is set to propel the growth in this market.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 6.9% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2015 to 2020 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Million and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Type, Treatment Type, Cause, Distribution Channel, Region |
| Regions Covered | North America; Latin America; Western Europe; Eastern Europe; APEJ; Japan; Middle East and Africa |
| Key Countries Profiled | USA, Canada, Brazil, Argentina, Germany, UK, France, Spain, Italy, Nordics, BENELUX, Australia & New Zealand, China, India, ASEAN, GCC, South Africa |
| Key Companies Profiled | F. Hoffmann-La Roche AG; GlaxoSmithKline plc; Eli Lilly and Company; Mayne Pharma; Cadila Pharmaceuticals; Teva Pharmaceutical Industries Ltd.; Pfizer; Endo International plc; Akervall Technologies, Inc.; Mylan N.V. |
| Customization | Available Upon Request |
The global bruxism management market is anticipated to reach USD 10.1 Billion in 2032.
North America is set to lead the bruxism management market in the forecast period.
F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Eli Lilly and Company, Mayne Pharma, Cadila Pharmaceuticals, and Teva Pharmaceutical Industries Ltd. are some of the renowned companies in the bruxism management market.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Bruxism Management Market Analysis 2017 to 2021 and Forecast, 2022 to 2032 5. Global Bruxism Management Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Product Type 5.1. Mouth Guards 5.2. Electric Stimulators 6. Global Bruxism Management Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Indication 6.1. Awake Bruxism 6.2. Sleep Bruxism 7. Global Bruxism Management Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By End User 7.1. Dental Clinics 7.2. Hospitals 7.3. Sleep Centers 7.4. Home Care Settings 8. Global Bruxism Management Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. East Asia 8.5. South Asia & Pacific 8.6. MEA 9. North America Bruxism Management Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 10. Latin America Bruxism Management Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 11. Europe Bruxism Management Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 12. East Asia Bruxism Management Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 13. South Asia & Pacific Bruxism Management Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 14. MEA Bruxism Management Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 15. Key Countries Bruxism Management Market Analysis 16. Market Structure Analysis 17. Competition Analysis 17.1. Ivoclar Vivadent AG 17.2. Ipsen Biopharmaceuticals, Inc. 17.3. BiTech Inc. 17.4. Alldent 17.5. DenTek Oral Care, Inc. 17.6. Carestream Dental 17.7. Patterson Dental Supply, Inc. 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Bruxism Management Market
